2018年7月16日，中國，上海。 今天，位于中國上海的生物醫(yī)藥公司禮進(jìn)生物宣布公司完成3000萬美元的B輪融資。本次融資由通和毓承領(lǐng)投，其他投資方包括Winfair Global和潤瓴資本。原有投資者M(jìn)orningside Ventures也參與了本輪投資。 禮進(jìn)生物由前艾伯維腫瘤研發(fā)資深科學(xué)家王結(jié)義博士于2016年創(chuàng)立，王結(jié)義博士在雅培/艾伯維工作二十二年，擁有豐富的抗癌新藥及腫瘤免疫研發(fā)經(jīng)驗(yàn)。禮進(jìn)生物致力于發(fā)明創(chuàng)造擁有自主知識(shí)產(chǎn)權(quán), 針對腫瘤等重大疾病的新藥。其擁有世界領(lǐng)先的交聯(lián)抗體技術(shù)平臺(tái)以及優(yōu)化刺激性抗體，尤其是其獨(dú)有的xLinkAb（交聯(lián)抗體）技術(shù)能夠有選擇性地激活腫瘤微環(huán)境特定受體，減少正常組織免疫副反應(yīng)。公司重點(diǎn)研發(fā)世界領(lǐng)先的腫瘤免疫激活性抗體和癌癥免疫組合治療，以期可以提高癌癥病人長期生存率。目前禮進(jìn)生物抗PD-1人源化單克隆抗體SSI-361已授權(quán)安科生物開發(fā)中國市場。
“我們認(rèn)為禮進(jìn)生物是一個(gè)極具潛力的投資機(jī)會(huì)。禮進(jìn)生物獨(dú)有的交聯(lián)抗體技術(shù)平臺(tái)可以有效解決當(dāng)前腫瘤免疫療法中出現(xiàn)的副反應(yīng)問題，并進(jìn)一步實(shí)現(xiàn)對某類受體的選擇性特異激活，有望進(jìn)一步拓展腫瘤免疫療法的靶標(biāo)以及適應(yīng)范圍”，通和毓承首席執(zhí)行官兼創(chuàng)始合伙人陳連勇博士表示：“相信公司在王結(jié)義博士的帶領(lǐng)下，可以為腫瘤患者帶來更多療效好副作用低的免疫治療藥物?！?/span>
本輪融資的資金會(huì)用于推動(dòng)禮進(jìn)生物目前研發(fā)管線中數(shù)個(gè)具有競爭力的全新的腫瘤免疫治療分子的臨床前開發(fā)以及未來進(jìn)入臨床開展臨床試驗(yàn)。禮進(jìn)生物還將利用募集得到的資金進(jìn)一步拓展其交聯(lián)抗體技術(shù)平臺(tái)的能力，研發(fā)更多相關(guān)適應(yīng)癥的全新免疫療法。本輪募資的順利完成也顯示出投資人對于禮進(jìn)生物擁有的巨大潛力，以及對公司領(lǐng)導(dǎo)層為患者和投資人回饋能力的信心。 通和毓承也將一如既往的加強(qiáng)對于領(lǐng)域內(nèi)革新性技術(shù)的投資，加快推進(jìn)相關(guān)藥物以及療法的開發(fā)與臨床實(shí)驗(yàn)。我們期待通過資本的助力，可以幫助禮進(jìn)生物進(jìn)一步釋放其研發(fā)能力，為癌癥免疫治療引入全新的藥物以及治療方案！
關(guān)于通和毓承資本
通和毓承是一家專注于醫(yī)療健康領(lǐng)域的領(lǐng)先投資機(jī)構(gòu)，對中美兩地市場均有深度聚焦和廣泛覆蓋。通和毓承擁有近40人的專業(yè)投資和運(yùn)營管理團(tuán)隊(duì)，在中國上海、香港和美國波士頓、帕羅奧多設(shè)有辦公室。目前共管理4支美元基金及3支人民幣基金，總管理資金規(guī)模逾百億人民幣，迄今累計(jì)投資和培育了逾70家企業(yè)。通和毓承由兩家專業(yè)且互補(bǔ)，輻射中美兩地的醫(yī)療健康領(lǐng)域投資機(jī)構(gòu)通和資本和毓承資本在2017年5月合并而成。合并后的通和毓承是行業(yè)內(nèi)規(guī)模最大的專業(yè)投資機(jī)構(gòu)之一，成為推動(dòng)跨太平洋兩岸生命科學(xué)及醫(yī)療健康領(lǐng)域內(nèi)創(chuàng)新型投資機(jī)會(huì)的有力引擎。
July 16th 2018, Shanghai, China.
Lyvgen Biopharma, a biotechnology company developing novel immunotherapies based in Shanghai, today announced the completion of a USD $30 million Series B funding round. 6 Dimensions Capital led this round of financing, with participation from Winfair Global, Runling Capital and existing Series A investor Morningside Ventures.
Lyvgen was founded in 2016 by Dr. Jieyi Wang, who most recently served as the Senior Principal Research Scientist at AbbVie. Dr. Wang brings over 22 years of experience from Abbott and AbbVie, and is a seasoned veteran in oncology and immunotherapy research. With Lyvgen’s industry leading cross-link antibody (xLinkAb) platform and co-stimulation agonist antibodies, the company is dedicated to developing first-in-class and best-in-class therapeutics for major diseases, such as cancer. Lyvgen’s xLinkAb technology could selectively activate specific receptors in the tumor microenvironment, while reducing immune-related adverse effects in the healthy tissue. Currently, the company is focused on developing combination therapy of tumor immune agonist antibody and cancer immunotherapy, in an effort to improve the long-term survival of cancer patients. Lyvgen has out-licensed its anti-PD-1 humanized monoclonal antibody product SSI-361 to Anhui Anke Biotechnology for market development in China. “We believe Lyvgen presents an investment opportunity with high potential. Its proprietary cross-link antibody platform could solve the toxicity issue in current cancer immunotherapies and enable selective activation of specific groups of receptors. These unique advantages could help the company expand the target and indication for cancer immunotherapy.” Dr. Leon Chen, CEO and Founding Partner of 6 Dimensions Capital, stated, “We believe that under the leadership of Dr. Wang, Lyvgen could develop more efficacious and better tolerated immunotherapies for cancer patients.” Proceeds from this financing will support the pre-clinical and future clinical studies for several promising immuno-oncology programs in Lyvgen’s pipeline. Lyvgen will also use funding from this round to further expand the capability of its cross-link antibody platform for immunotherapies in more suitable indications. The successful completion of this financing round demonstrated confidence from its investors in Lyvgen’s potential and in its leadership team to deliver value to patients and investors. 6 Dimensions Capital will continue to invest in innovative healthcare technologies to propel the pre-clinical and clinical studies of innovative therapeutics. With investment in this round, we hope to help Lyvgen unleash its potential and develop novel immunotherapies. About 6 Dimensions Capital
6 Dimensions Capital is a leading healthcare focused investment firm with an in-depth focus and extensive coverage across China and the United States. It consists of a team of about 40 investment and operation professionals with offices in Shanghai, Hong Kong, Boston, and Palo Alto. The firm currently has US$1.6 billion assets under management through 4 US dollar-denominated and 3 RMB-denominated funds and has cultivated a portfolio of more than 70 companies.
6Dimensions Capital was formed in May 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures, two prominent and complementary China-U.S. healthcare investment firms. The merger has created a powerhouse that aims to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific.
關(guān)于煜森資本 煜森資本成立于2016年，聚焦國際先進(jìn)的生物醫(yī)學(xué)科技，旨在打造一流的醫(yī)療健康創(chuàng)業(yè)和投融資平臺(tái)。核心團(tuán)隊(duì)由一批業(yè)內(nèi)資深企業(yè)家、投資人和職業(yè)經(jīng)理人組成，擁有豐富的研發(fā)、管理、創(chuàng)業(yè)、投資和資本運(yùn)作經(jīng)驗(yàn)，并擁有深厚的行業(yè)資源。煜森資本核心業(yè)務(wù)，包括天使投資、共同創(chuàng)業(yè)、財(cái)務(wù)顧問和專項(xiàng)投資基金四大板塊。煜森資本秉承“投資并與企業(yè)共成長”的理念，致力于成為企業(yè)的緊密合作伙伴，推動(dòng)和協(xié)助企業(yè)共同發(fā)展，與投資和服務(wù)的企業(yè)攜手構(gòu)建中國醫(yī)療健康新生態(tài)。
